The Critical Path Institute (C-Path) is launching a task force to advance the development of therapies for limb-girdle…
Articles by Steve Bryson, PhD
A noninvasive quantitative MRI, or qMRI, was found to detect early muscle abnormalities among people with limb-girdle muscular dystrophy…
Avidity Biosciences‘ delpacibart zotadirsen, or del-zota for short — formerly called AOC 1044 — was found to safely increase…
One year of losmapimod taken twice a day improved or stabilized upper limb function and muscle strength in adults…
After three years of treatment with Capricor Therapeutics’ experimental cell therapy CAP-1002, people with Duchenne muscular dystrophy (DMD)…
A $250,000 award from the Parent Project Muscular Dystrophy (PPMD) will support the establishment of Baby Duchenne, a collaborative…
Researchers have discovered a new, unrecognized type of muscular dystrophy that’s caused by inherited mutations in the SNUPN gene,…
Up to eight years of Exondys 51 treatment (eteplirsen or AVI-4658) extended survival in Duchenne muscular dystrophy (DMD)…
Regulators in France and Italy have given Atamyo Therapeutics the green light to launch a clinical trial testing ATA-200,…
A cell-based study revealed the biological mechanism behind the increased tendency for people with myotonic dystrophy type 2 (DM2)…